Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.36 |
| ▸ | ESR1 | P03372 | 3/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | SGK1 | O00141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29660078 | 1.00 | APP (0.41) | APPAKR1C3AKR1C2LTB4RLTB4R2 | |
| SCHEMBL17434660 | 0.84 | ESR1 (0.34) | ESR1ESR2CYP3A4ALDH1A1 | |
| SCHEMBL29962699 | 0.84 | ESR1 (0.34) | ESR1ESR2CYP3A4ALDH1A1 | |
| SCHEMBL8848023 | 0.84 | APP (0.44) | APPAKR1C3AKR1C2LTB4RLTB4R2 | |
| SCHEMBL20004834 | 0.82 | EPHX2 (0.43) | APPAKR1C3AKR1C2LTB4RLTB4R2 | |
| SCHEMBL23629562 | 0.82 | CNR2 (0.47) | ESR1ESR2ALDH1A1 | |
| SCHEMBL30880291 | 0.82 | CNR2 (0.47) | ESR1ESR2ALDH1A1 | |
| SCHEMBL10247649 | 0.82 | ESR1 (0.33) | ESR1ESR2 | |
| SCHEMBL30880292 | 0.82 | CNR2 (0.47) | ESR1ESR2ALDH1A1 | |
| SCHEMBL19296748 | 0.81 | ESR1 (0.33) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112047829-B | Synthesis method of alcaine intermediate 2- (4-ethyl-3-iodophenyl) -2-methylpropanoic acid | 成都艾必克医药科技有限公司 | 2023-05-26 | — | — | CN | claimed |
| CN-109438218-B | Synthesis method of hydrochloric acid neritinib intermediate 2- (4-ethyl-3-iodophenyl) -2-methylpropanoic acid | 成都艾必克医药科技有限公司 | 2021-04-09 | — | — | CN | claimed |
| CN-112047829-A | Synthetic method of hydrochloric acid Alininib intermediate 2- (4-ethyl-3-iodophenyl) -2-methylpropanoic acid | 成都艾必克医药科技有限公司 | 2020-12-08 | — | — | CN | claimed |
| CN-109438218-A | A kind of hydrochloric acid Ai Le replaces the synthetic method of Buddhist nun's intermediate 2- (4- ethyl -3- iodophenyl) -2 Methylpropionic acid | 成都艾必克医药科技有限公司 | 2019-03-08 | — | — | CN | claimed |
| EP-4321514-B1 | COMPOUND HAVING ALK INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | CGENETECH SUZHOU CHINA CO LTD (CN) | 2025-12-03 | — | — | EP | disclosed |
| EP-3848361-B1 | METHOD OF PRODUCING TETRACYCLIC COMPOUND | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-01-22 | — | — | EP | disclosed |
| US-20240246927-A1 | COMPOUNDS WITH ALK INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREOF | CGENETECH (SUZHOU, CHINA) CO., LTD. (CN) | 2024-07-25 | — | — | US | disclosed |
| CN-112585126-B | Process for preparing tetracyclic compounds | 中外制药株式会社 | 2024-05-07 | — | — | CN | disclosed |
| US-11939322-B2 | Method for producing tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-03-26 | — | — | US | disclosed |
| EP-4321514-A1 | COMPOUND HAVING ALK INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | CGeneTech (Suzhou, China) Co., Ltd. (CN) | 2024-02-14 | — | — | EP | disclosed |
| CN-115340523-B | Compound with ALK inhibitory activity and preparation method and application thereof | 盛世泰科生物医药技术(苏州)股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-117024410-A | Airotinib intermediate and preparation method thereof | 上海药坦药物研究开发有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| CN-102459172-A | Tetracyclic compounds | CHUGAI PHARMACEUTICAL CO LTD | 2012-05-16 | — | — | CN | disclosed |
| EP-2441753-A1 | TETRACYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-04-18 | — | — | EP | disclosed |
| EP-2441753-A1 | TETRACYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
| WO-2010143664-A1 | TETRACYCLIC COMPOUND | 中外製薬株式会社 (JP) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083488-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | APP 736/4885AKR1C3 1976/4885AKR1C2 1421/4885 |
| US-20240246927-A1 | COMPOUNDS WITH ALK INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREOF | ALK, ACVR1, ALKBH3 | APP 3413/4885AKR1C3 998/4885AKR1C2 830/4885 |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | APP 736/4885AKR1C3 1976/4885AKR1C2 1421/4885 |
| US-11939322-B2 | Method for producing tetracyclic compound | CYP1B1, CYP4B1, PAICS | APP 2816/4885AKR1C3 2166/4885AKR1C2 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.